Pfizer (NYSE:PFE) and Arvinas (NASDAQ:ARVN) announced Saturday their plans to submit a new drug application with the Food and Drug Administration (FDA) in H2 2025 targeting the U.S. approval of their jointly developed breast cancer therapy, vepdegestrant.

The decision comes